ExodusPoint Capital Management LP Buys 242,263 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

ExodusPoint Capital Management LP boosted its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 440.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 297,234 shares of the company’s stock after acquiring an additional 242,263 shares during the period. ExodusPoint Capital Management LP owned 0.38% of Kura Oncology worth $2,589,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Kura Oncology by 14.6% during the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock worth $41,973,000 after purchasing an additional 615,211 shares during the last quarter. Trexquant Investment LP grew its holdings in Kura Oncology by 867.8% during the fourth quarter. Trexquant Investment LP now owns 566,945 shares of the company’s stock valued at $4,938,000 after purchasing an additional 508,362 shares during the period. Point72 Asset Management L.P. purchased a new stake in Kura Oncology in the third quarter worth $3,695,000. Wealthfront Advisers LLC bought a new stake in shares of Kura Oncology in the fourth quarter valued at $1,289,000. Finally, Barclays PLC raised its stake in shares of Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after buying an additional 84,563 shares during the period.

Analysts Set New Price Targets

Several brokerages recently weighed in on KURA. Scotiabank decreased their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. UBS Group reduced their target price on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. StockNews.com upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Friday. Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research note on Thursday, February 27th. Finally, Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and an average price target of $25.50.

Insider Transactions at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last quarter. Insiders own 5.50% of the company’s stock.

Kura Oncology Trading Down 2.2 %

Shares of KURA stock opened at $5.76 on Tuesday. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $23.48. The business’s fifty day moving average is $7.64 and its 200 day moving average is $11.34. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company has a market capitalization of $465.15 million, a PE ratio of -2.44 and a beta of 0.83.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million. On average, equities research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.